Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Mikhail N KosiborodSteen Z AbildstrømBarry A BorlaugJaved ButlerSøren RasmussenMelanie DaviesG Kees HovinghDalane W KitzmanMarie L LindegaardDaniél V MøllerSanjiv J ShahMarianne B TreppendahlSubodh VermaWalter AbhayaratnaFozia Z AhmedVijay ChopraJustin EzekowitzMichael FuHiroshi ItoMałgorzata LelonekVojtech MelenovskyBela MerkelyJulio NunezEduardo Roque PernaMorten SchouMichele SenniKavita SharmaPeter Van der MeerDirk von LewinskiDennis WolfMark C Petrienull nullPublished in: The New England journal of medicine (2023)
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).